Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 7/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | ACACA | Q13085 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17050831 | 0.88 | KDM4E (0.55) | ACACBKDM4EALDH1A1L3MBTL1ACACA | |
| SCHEMBL17050453 | 0.82 | ACACB (0.53) | ACACBKDM4EALDH1A1L3MBTL1ACACA | |
| SCHEMBL17050518 | 0.81 | ACACB (0.70) | ACACBACACACYP3A4CYP2C9POLB | |
| SCHEMBL17050839 | 0.80 | TTR (0.48) | ACACBKDM4EALDH1A1L3MBTL1ACACA | |
| SCHEMBL17050832 | 0.80 | ACACB (0.57) | ACACBACACACYP3A4CYP2C9POLB | |
| SCHEMBL17050830 | 0.80 | ACACB (0.52) | ACACBKDM4EL3MBTL1ACACACYP3A4 | |
| SCHEMBL17050840 | 0.79 | ACACB (0.68) | ACACBACACACYP3A4CYP2C9POLB | |
| SCHEMBL17050834 | 0.79 | ACACB (0.71) | ACACBACACACYP3A4CYP2C9POLB | |
| SCHEMBL8006810 | 0.78 | ALDH1A1 (0.61) | ACACBKDM4EALDH1A1L3MBTL1POLB | |
| SCHEMBL17050525 | 0.78 | ACACB (1.00) | ACACBACACACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246938-A1 | NOVEL OLEFIN DERIVATIVE | ACSS2, ACACB, ACAT2 | ACACB 2/4885KDM4E 2675/4885ALDH1A1 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.